Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07570082
PHASE1

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

Sponsor: Crinetics Pharmaceuticals Inc.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.

Official title: A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants

Key Details

Gender

All

Age Range

19 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2026-05-06

Completion Date

2026-12-31

Last Updated

2026-05-06

Healthy Volunteers

Yes

Interventions

DRUG

Atumelnant

Atumelnant, tablets

DRUG

Carbamazepine

CYP3A4 inducer

DRUG

Midazolam

CYP3A4 substrate

DRUG

Digoxin

P-gp substrate

DRUG

Metformin

MATE1/2-K substrate

Locations (1)

Crinetics Study Site

Lincoln, Nebraska, United States